AxoGen (AXGN) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of AxoGen (NASDAQ: AXGN) in the last few weeks:

• 2/28/2026 – AxoGen was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/24/2026 – AxoGen had its “outperform” rating reaffirmed by Citigroup Inc..
• 2/24/2026 – AxoGen had its price target raised by Citizens Jmp from $34.00 to $42.00. They now have a “market outperform” rating on the stock.
• 2/23/2026 – AxoGen had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $41.00 price target on the stock.
• 2/19/2026 – AxoGen is now covered by Wells Fargo & Company. They set an “overweight” rating and a $40.00 price target on the stock.
• 2/19/2026 – AxoGen is now covered by Wells Fargo & Company. They set an “overweight” rating and a $40.00 price target on the stock.
• 1/23/2026 – AxoGen was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Insider Transactions at AxoGen

In other news, Director Amy Mcbride Wendell sold 43,684 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $29.31, for a total value of $1,280,378.04. Following the completion of the sale, the director directly owned 93,826 shares of the company’s stock, valued at $2,750,040.06. This trade represents a 31.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Lindsey Marie Hartley sold 14,812 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $29.86, for a total value of $442,286.32. Following the completion of the sale, the chief financial officer owned 31,376 shares in the company, valued at approximately $936,887.36. This trade represents a 32.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 301,680 shares of company stock valued at $9,174,052. Company insiders own 2.78% of the company’s stock.

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.